IONLACE is focused on proteomics at scale, integrating real-world AI with synthetic biology to provide unique, high-resolution data for advancing human health.

IONLACE

Ginkgo Bioworks Holdings, Inc., together with its subsidiaries, develops platform for cell programming. Its platform is used to program cells to enable biological production of products, such as novel therapeutics, food ingredients, and chemicals derived from petroleum. The company serves various end markets, including specialty chemicals, agriculture, food, consumer products, and pharmaceuticals. Ginkgo Bioworks has a partnership with Selecta Biosciences, Inc. to develop ImmTOR technology platform. Ginkgo Bioworks Holdings, Inc. was founded in 2008 and is headquartered in Boston, Massachusetts.

Austin Che

Tom Knight

Jason Kelly

Barry Canton

Reshma Shetty

Ginkgo Bioworks Holdings, Inc.

Pivot Bio is a sustainable agriculture company that delivers patented crop nutrition technologies to reliably and productively grow food while reducing the negative impacts of synthetic fertilizer.

Alvin Tamsir

Karsten Temme

Pivot Bio

Sengenics is a company that develops and provides immunoproteomics technologies and services for biomarker discovery. The company markets two products, i-Ome Cancer and i-Ome Discovery, which are protein microarrays that allow customers to profile autoantibodies against a large number of protein antigens. Sengenics' technology is based on a patented KREX® protein folding technology that ensures that the proteins on the microarrays are correctly folded, increasing the accuracy and reproducibility of the results. Sengenics is also a certified Service Provider for Asia through their partnership with SML Meditree.

Metric
Company Name	IONLACE	Ginkgo Bioworks Holdings, Inc.	Pivot Bio	Sengenics
Symbol		DNA
MSH ID	COM:IONLACE	COM:GINKGOBIOWORKS	COM:PIVOTBIO	COM:SENGENICS
Market	PRIVATE	STOCKS	PRIVATE	PRIVATE
Sector	Healthcare & Health Services	Healthcare	Consumer Goods	Technology
Industry	Biotechnology	Biotechnology	Agriculture	Biotechnology
Country	US	US	US	US
Stage		Grant
Employee Count		1.22K	430
Website	ionlace.com	ginkgobioworks.com	pivotbio.com	sengenics.com
LinkedIn		ginkgo-bioworks	pivot-bio
Founders

Metric
Market Cap		725.64M
Enterprise Value
Monthly Web Traffic		20.69K
Web Traffic Growth		-0.17
Valuation
Raised Capital

Metric
Revenue		251.46M
Revenue (LTM)
Revenue (NTM)
Gross Profit		142.64M
EBITDA		-600.68M
Operating Income		-672.23M
Net Income		-892.87M
EPS		-0.46
Diluted EPS		-0.46
Revenue 2022
Revenue 2023
Revenue 2024
Revenue 2025
Revenue 2026

Metric
Revenue Growth (LTM)
Revenue Growth (NTM)
Gross Profit Growth (LTM)
EBITDA Growth (LTM)
Net Income Growth (LTM)
14-Day Growth Score
28-Day Growth Score
90-Day Growth Score
365-Day Growth Score

Metric
Gross Profit Margin		0.75
Operating Profit Margin		-3.34
EBITDA Margin		-2.39
Net Profit Margin		-3.55
Return on Equity		-0.65
Return on Assets		-0.54
Return on Capital Employed		-0.51

COM:IONLACE

IONLACE

Company Overview

Market Metrics

Financial Performance

Growth Metrics

Profitability Ratios

Valuation Multiples

Operational Metrics

Cash Flow Metrics

Balance Sheet Metrics

Efficiency Metrics

Metric
P/E Ratio		-2.78
P/B Ratio		1.90
Revenue Multiple (LTM)
Revenue Multiple (NTM)
EBITDA Multiple (LTM)
EBITDA Multiple (NTM)
Price to Sales Ratio		93.70
EV Multiple		-1.34

Metric
Days Sales Outstanding		73.17
Days Payables Outstanding		50.57
Days Inventory Outstanding		0.27
Operating Cycle		46.33
Cash Conversion Cycle		-7.39
Asset Turnover		0.15

Metric
Operating Cash Flow		-295.50M
Free Cash Flow		-336.30M
Cash Flow to Debt		-0.63
Operating Cash Flow/Sales		-1.14
Free Cash Flow Yield		-0.16

Metric
Cash & Equivalents		948.86M
Accounts Receivable		50.07M
Inventory		46K
Goodwill		49.24M
Debt to Capitalization		0.35
Debt to Assets		0.20
Current Ratio		6.78
Quick Ratio		5.98

Metric
Rule of 40 (LTM)
Rule of 40 (NTM)
Stock Comp to Revenue		0.94
R&D to Revenue		2.05
SG&A to Revenue		1.32